Barclays
DYN icon

Barclays’s Dyne Therapeutics DYN Stock Holding History

Barclays’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-63,300
Closed -$1.24M – 5147
2025
Q4 		$1.24M Hold
63,300
– – ﹤0.01% 3289
2025
Q3 		$801K Buy
+63,300
New +$722K ﹤0.01% 3506

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Barclays's DYN Position: Q1 2026 in Review

Barclays reduced its Dyne Therapeutics (DYN) stake by 92% in Q1 2026, selling an estimated $7.11M and leaving 36,569 shares worth $663K. The position accounts for ﹤0.01% of the portfolio, ranked #3011.

Barclays first reported a position in DYN in Q1 2022 and has held it in 17 quarters since. The position peaked at $8.78M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Barclays held 36,569 shares of Dyne Therapeutics worth $663K as of Q1 2026.
  • Barclays sold 412,089 Dyne Therapeutics shares in Q1 2026, an estimated $7.11M.
  • Dyne Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3011 holding.
  • Barclays first reported a position in Dyne Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Dyne Therapeutics position peaked at $8.78M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.